Biochemical effects of a calcium supplement in postmenopausal women with primary hyperparathyroidism
- PMID: 8150422
- DOI: 10.1055/s-2007-1000769
Biochemical effects of a calcium supplement in postmenopausal women with primary hyperparathyroidism
Abstract
Oral calcium loading is known to decrease parathyroid hormone levels in primary hyperparathyroidism. We have examined the effects of a calcium supplement on bone resorption in postmenopausal primary hyperparathyroidism. Fasting blood and urine samples were obtained in 12 postmenopausal women (median age 64 yr) with primary hyperparathyroidism associated with mild hypercalcemia (plasma calcium < 3.00 mmol/l). Further samples were obtained 12 hours after a 1 g calcium supplement given at 2100 h. After calcium administration there were rises in plasma ionized calcium (p < 0.02), plasma phosphate (p < 0.05) and the renal tubular maximum reabsorption capacity for phosphate (p < 0.01) and falls in parathyroid hormone (p < 0.05) and the renal tubular maximum reabsorption capacity for calcium (p < 0.05). The urinary calcium/creatinine increased (p < 0.01) and the urinary hydroxyproline/creatinine (p < 0.02) fell. These results indicate that calcium loading inhibits bone resorption in postmenopausal women with mild primary hyperparathyroidism.
Similar articles
-
Treatment of postmenopausal hyperparathyroidism with norethindrone. Effects on biochemistry and forearm mineral density.Arch Intern Med. 1987 Apr;147(4):681-5. Arch Intern Med. 1987. PMID: 3827457
-
Normocalcemic primary hyperparathyroidism: resistance to PTH effect on tubular reabsorption of calcium.Miner Electrolyte Metab. 1984;10(5):301-8. Miner Electrolyte Metab. 1984. PMID: 6493158
-
1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.Dan Med Bull. 2008 Nov;55(4):186-210. Dan Med Bull. 2008. PMID: 19232159 Review.
-
Acute changes in calcium homeostasis during treatment of primary hyperparathyroidism with risedronate.J Clin Endocrinol Metab. 1993 Oct;77(4):1067-71. doi: 10.1210/jcem.77.4.8408454. J Clin Endocrinol Metab. 1993. PMID: 8408454
-
Nonoperative management of hyperparathyroidism: present and future.Curr Opin Oncol. 2001 Jan;13(1):33-8. doi: 10.1097/00001622-200101000-00007. Curr Opin Oncol. 2001. PMID: 11148683 Review.
Cited by
-
Contemporary Medical Management of Primary Hyperparathyroidism: A Systematic Review.Front Endocrinol (Lausanne). 2017 Apr 20;8:79. doi: 10.3389/fendo.2017.00079. eCollection 2017. Front Endocrinol (Lausanne). 2017. PMID: 28473803 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources